国籍英式/美式bbb 出生年份: 1964
A scientist by training, 约翰D. 年轻的 has nearly 35 years of experience in the healthcare industry and brings a wealth of experience in leadership, 策略, business development and commercialization of innovative medicines to the 全国十大赌博官网制药 董事会. He joined Pfizer in 1987 as a sales representative and held positions of increasing seniority across the company, including as a member of Pfizer’s Executive Leadership Team from 2012. As Pfizer’s Group President and Chief Business Officer from 2019 until 2022, John also played an integral role in the development and delivery of the Pfizer-BioNTech COVID-19 vaccine.
专业经验
- Senior advisor to the CEO, Pfizer, US (January-June 2022)
- Group president and chief business officer, Pfizer, US (2019-2022)
- Group president, innovative health business, Pfizer, US (2018)
- Group president, essential health business, Pfizer, US (2014-2017)
- President and general manager, global primary care business unit, Pfizer, US (2012-2013)
- Regional president, primary care business unit for 欧洲 and Canada, Pfizer, UK (2009-2012)
- Various managerial positions, Pfizer, UK and Australia (1987–2008)
授权
- 董事会成员, Johnson Controls International, Ireland
- 董事会成员，Arvinas Inc，美国
- 董事会成员, Imbria Pharmaceuticals, US
- 董事会成员, 黑尔on, UK (2022-February 2023)
- 董事会成员, GSK Consumer Health Joint Venture, UK (2019-2022)
- 董事会成员, Biotechnology Innovation Organization (BIO), US (2018-2021)
- US bio-pharmaceutical representative, UK Government Life Sciences Council, UK (2007-2021)
- 董事会成员, National Committee for US China Relations, US (2014-2017)
- 董事会成员, 欧洲an Federation of Pharmaceutical Industries and Associations (EFPIA), 比利时(2012 - 2017)
教育
- Master of Business Administration, University of Strathclyde, UK
- Bachelor of Science in biological sciences, University of Glasgow, UK
关键技能
- 医药/医疗/ R&D
- 领导/管理
- 财务/会计
- Law/regulatory/risk management